ESC 2022 In a subpopulation of patients with rheumatic heart disease and AF, the effect of rivaroxaban vs. VKA was examined for the composite outcome of stroke, systemic embolism, MI and death from vascular or unknown cause.

Although the newer risk scores tended to have better predictive abilities than the conventional scores, research on external validation and calibration is required to confirm this.

ESC 2022 eBRAVE-AF tested the efficacy of a digital screening strategy using ordinary smartphones for detecting treatment-relevant AF in an elderly population in a head-to-head comparison with usual care.

ESC 2022 A digital screening strategy using normal smartphones more than doubled the detection rate of AF.

Three speakers will provide guidance and insights on the treatment of patients with atrial fibrillation or venous thromboembolism in clinical practice. Watch the presentations and answer the questions! NEW: Content of the course also available as text

If HFpEF patients also have atrial fibrillation and/or flutter, they are at increased risk of HF hospitalization or CV death, as shown by a post-hoc analysis of the PARAGON-HF trial.

Prof. Storey guides us through the ESC guidelines for the prevention of thromboembolic events in patients with atrial fibrillation.

ACC 2022 The factor XIa inhibitor asundexian lowers bleeding rate compared with apixaban in patients with AF in the phase 2 PACIFIC-AF trial.

Prof. Hohnloser talks about innovations in screening for AF. He also gives an overview of clinical outcomes with anticoagulation therapy in AF and discusses updates in recent AF guidelines.

The results of an observational study suggest that treatment with DOAC may be associated with a positive net clinical benefit compared with VKA and no anticoagulation treatment in patients with AF at low stroke risk.

Andexanet alfa specifically binds and sequesters factor Xa inhibitors. A study investigated the efficacy and safety of andexanet alfa in patients on edoxaban with acute major bleeding.

AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.